REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Clinical trials for REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED trials appear
Sign up with your email to follow new studies for REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo aims to outsmart tough lymphoma
Disease control Recruiting nowThis study is for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It tests a combination of two drugs: epcoritamab, which helps the immune system attack cancer cells, and ibrutinib, which blocks signals that help cance…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated May 26, 2026 03:30 UTC
-
New combo therapy aims to boost lymphoma remission after transplant
Disease control Recruiting nowThis study tests whether adding the drug epcoritamab to standard chemotherapy and a stem cell transplant can improve outcomes for people with large B-cell lymphoma that has returned or not responded to prior treatment. About 25 adults will receive epcoritamab plus chemotherapy be…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Joseph Tuscano • Aim: Disease control
Last updated May 26, 2026 03:26 UTC
-
New drug combo offers hope for hard-to-treat lymphoma patients before transplant
Disease control Recruiting nowThis study tests a two-step treatment for adults with large B-cell lymphoma that has returned or not responded to standard therapy. First, patients receive tafasitamab and lenalidomide, then a chemotherapy combo called ICE. The goal is to shrink or eliminate cancer before a stem …
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated May 26, 2026 03:25 UTC
-
New combo therapy aims to beat back stubborn lymphoma before stem cell transplant
Disease control Recruiting nowThis study tests a new drug combination (epcoritamab plus chemotherapy) given before a stem cell transplant for people with a type of aggressive lymphoma (DLBCL) that has come back or not responded to prior treatments. The goal is to see if this approach can completely eliminate …
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 03:24 UTC
-
New 5-Drug cocktail ViPOR targets Hard-to-Treat lymphomas
Disease control Recruiting nowThis study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to prior therapy. The goal is to see how many patients achieve co…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 22, 2026 13:55 UTC
-
New combo may help more lymphoma patients qualify for potentially curative CAR-T
Disease control Recruiting nowThis study tests whether giving two drugs—golcadomide and rituximab—before CAR-T cell therapy can help more people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. The goal is to control the disease so patients can proceed to CAR-T, whi…
Matched conditions: REFRACTORY HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 19, 2026 11:48 UTC